The Association Between Chlorhexidine Bathing and Central Line-Associated Infections in Medical Intensive Care Units
Study Details
Study Description
Brief Summary
We conducted a retrospective observational cohort study assessing the relationship between regular bathing using 2% CHG wipes every other day and the occurrence of central line-associated infections (CLABSI) in patients within the medical intensive care unit (MICU).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study defined the post-intervention period as July 1, 2017, to June 30, 2022. During this period, one of the three medical intensive care units (MICUs) in NTUH implemented chlorhexidine gluconate (CHG) bathing as part of their daily care routine (CHG group). This decision was made in response to a higher incidence rate of vancomycin-resistant Enterococcus (VRE) bacteremia observed in that particular MICU during the preceding six months (pre-intervention period: January 1, 2017, to June 30, 2017), compared to the other two MICUs. The remaining two MICUs continued to provide usual care, which involved bathing patients with towels soaked in water and soap on a daily basis.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| chlorhexidine group Patients were bathed one day involving the use of wipes soaked in a 2% chlorhexidine gluconate (CHG) solution and the next day using a towel soaked with water and soap during the MICU stays. |
Other: Chlorhexidine bathing
The procedure involved pouring an entire bottle (200ml) of 2% CHG solution (PBF Biotech, Taipei, Taiwan) onto a pre-packed set of eight single-use cotton wipes before each bathing session. A minimum of six wipes were required to thoroughly cover the entire body, including the bilateral upper and lower extremities, front and back of the trunk, perineum, and buttocks.
|
| usual care group Patients were bathed with towels soaked in water and soap on a daily basis during the MICU stays. |
Outcome Measures
Primary Outcome Measures
- central line-associated bloodstream infections [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
the incidence rate of intensive care unit acquired central line-associated bloodstream infections
- multidrug-resistant organisms bacteremia [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
the incidence of CLABSIs with blood cultures positive for multidrug-resistant organisms
Secondary Outcome Measures
- ICU length of stay [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
the total duration of the patient's ICU stay (days)
- hospital length of stay [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
the total duration of the patient's hospital stay (days)
- ICU mortality [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
whether the patient has died during their stay in the ICU
- hospital mortality [Will be surveyed retrospectively through the study period (January 2017 to June 2022)]
whether the patient has died during their stay in the hospital
Eligibility Criteria
Criteria
Inclusion Criteria:
- all patients who were admitted to the MICU between January 2017 and June 2022
Exclusion Criteria:
- patients aged under 18 years old
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Taiwan University Hospital | Taipei | Taiwan | 100 |
Sponsors and Collaborators
- National Taiwan University Hospital
Investigators
- Principal Investigator: Yi-Chen Lin, National Taiwan University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 202302031RINC